Literature DB >> 12703673

Difference in the use of preventive services between fee-for-service plans and HMOs: is more better?

Y Richard Wang1, Mark V Pauly.   

Abstract

OBJECTIVE: Based on the US Preventive Services Task Force recommendations, we studied how health insurance type, ie, fee-for-service (FFS) or health maintenance organization (HMO), affects the utilization of preventive services of differing effectiveness. STUDY
DESIGN: Household survey data from the 1993 and 1994 National Health Interview Surveys.
METHODS: We compared the use of mammograms, Pap smears, blood pressure measurements, counseling about hormone replacement therapy (HRT), and general physical examinations in FFS plans and HMOs. We used the bivariate probit model to control for selection bias caused by the unobservable factors in the choice of health insurance type.
RESULTS: Enrollees in HMOs obtained more Pap smears, blood pressure measurements, mammograms (women 40 to 49 years old), and general physical examinations than enrollees in FFS plans. No significant difference was found between FFS plans and HMOs for the use of mammograms (women aged 30 to 39 years and 50 to 64 years) or HRT counseling. The correlation ratios from bivariate probit estimations indicated no selection bias favoring HMOs; for some preventive services, selection bias favored FFS plans.
CONCLUSIONS: Compared with enrollees in FFS plans, persons in HMOs used more preventive services, including less effective ones. Not controlling for selection bias underestimated the HMO effect.

Entities:  

Mesh:

Year:  2003        PMID: 12703673

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  1 in total

1.  Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study.

Authors:  Jinoos Yazdany; Chris Tonner; Laura Trupin; Pantelis Panopalis; Joann Z Gillis; Aimee O Hersh; Laura J Julian; Patricia P Katz; Lindsey A Criswell; Edward H Yelin
Journal:  Arthritis Res Ther       Date:  2010-05-12       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.